Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 351 results found. Search for [ Serum Institute ]

Results 1 to 21 of 351
PB Jayakumar & Joe C Mathew
October 26, 2020
Zydus Cadila's COVID-19 candidate vaccine ZyCov-D, which is currently undergoing second phase of clinical trials in India, is likely to enter Phase III final stage of clinical trials by December 2020


BusinessToday.In
October 26, 2020
Sharing a BusinessToday.In report stating that the new nasal vaccine can be a game-changer for COVID-19 testing, Shaw tweeted that these inoculations will be far easier to deliver than intra muscular injections


BusinessToday.In
October 26, 2020
The outcome of immunogenicity blood tests conducted on a subgroup of older study participants echoed data published in July this year that revealed that the coronavirus vaccine produced robust immune responses in healthy adults aged 18-55 years


PB Jayakumar | Joe C Mathew
October 25, 2020
Coronavirus vaccine administered through the intramuscular injection route protects the lower lungs but not the upper lung. Nasal vaccines can protect the lungs completely and stop transmission and also infection


BusinessToday.In
October 23, 2020
Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is expected to be at least 60 per cent effective


BusinessToday.In
New Delhi, October 23, 2020
India's smartphone shipments hit record high in Q3 2020; Xiaomi, Samsung, Vivo top charts; Bank credit rises to Rs 103.44 lakh crore; The world's largest vaccine maker by volume, Serum Institute of India (SII), is readying one billion doses of five different COVID-19 vaccines worldwide before the end of 2021-22. Watch this and more news on News Blast.


Rashi Bisaria
New Delhi, October 23, 2020
Serum to launch 5 COVID-19 vaccines by 2021 end; floats new firmThe world's largest vaccine maker by volume, Serum Institute of India (SII), is readying one billion doses of five different COVID-19 vaccines worldwide before the end of 2021-22. Serum has floated a new company Serum Institute Life Sciences (SILS) that will exclusively focus on developing, producing and supplying pandemic vaccines. SILS is owned by the Pune-based billionaire Cyrus Poonawala and his son Adar Poonawala.Maharasht...


Rashi Bisaria
New Delhi, October 23, 2020
Serum to launch 5 COVID-19 vaccines by 2021 end; floats new firmThe world's largest vaccine maker by volume, Serum Institute of India (SII), is readying one billion doses of five different COVID-19 vaccines worldwide before the end of 2021-22. Serum has floated a new company Serum Institute Life Sciences (SILS) that will exclusively focus on developing, producing and supplying pandemic vaccines. SILS is owned by the Pune-based billionaire Cyrus Poonawala and his son Adar Poonawala.Maharashtra...


PB Jayakumar
October 22, 2020
Serum Institute of India (SII) has teamed up with Merck KGaA, Germany, to develop COVID-19 fighting monoclonal antibodies (mAbs), made by cloning a unique white blood cell to increase immunity and fight diseases, along with drug research driven nonprofit scientific research organization IAVI and Scripps Research


BusinessToday.In
October 22, 2020
Covaxin, the COVID-19 vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has received the approval of Drugs Controller General of India (DCGI's) Expert Committee to start the final phase of trials


PB Jayakumar & Joe C Mathew
October 22, 2020
Serum has floated a new company Serum Institute Life Sciences (SILS) that will exclusively focus on developing, producing and supplying pandemic vaccines


PB Jayakumar & Joe C Mathew
October 22, 2020
There is not a single instance in history of a vaccine that has been discontinued


BusinessToday.In
October 22, 2020
Bharat Biotech Phase 3 trials: The volunteers would be given two doses of the experimental vaccine in a gap of 28 days


BusinessToday.In
October 22, 2020
Notably, Serum Institute of India is working with AstraZeneca and Oxford University to conduct trials and produce their vaccine candidate once it receives the required regulatory approvals


BusinessToday.In
October 20, 2020
Speaking during The Wall Street Journal's annual Tech Live conference on October 19, Moderna CEO Stephane Bancel said if satisfactory interim results from the study take longer to get, government authorisation of the COVID-19 vaccine may not happen until early next year


BusinessToday.In
October 19, 2020
Presently, there are around 40 different coronavirus vaccines in various stages of human clinical trials, comprising one being developed by Oxford University and AstraZeneca, which is already in an advanced stage of testing


BusinessToday.In
October 19, 2020
Chebrolu's invention is based on in-silico methodology. In this, a lead molecule selectively binds with spike protein of COVID-19. She is now planning to work with scientists who are working tirelessly to find vaccine against COVID-19


Joe C Mathew
October 18, 2020
Coronavirus vaccine: While there are no intranasal COVID-19 vaccines under trial in India at the moment, the two companies will pursue clinical trials of such vaccines in India in the coming months


PTI
October 17, 2020
Modi insisted on continued social distancing and COVID-appropriate behaviour such as wearing masks, regularly washing hands and sanitation, especially during upcoming festival season


BusinessToday.In
New Delhi, October 17, 2020
COVID-19 led to largest global economic contraction in 80 years: World Bank, IMFThe World Bank and the International Monetary Fund said the global economic contraction caused by the ongoing coronavirus pandemic is the largest in the last eight decades, raising the world poverty rate, exacerbating inequalities and damaging long-term economic growth prospects. The WB and IMF concluded their annual meeting here on Friday, which heavily revolved around the impact of COVID-19.India gained over a...


PAGES 1 OF 18  12345